Replete Pharmaceuticals Private Limited
Manufactures, trades, imports, and exports pharmaceutical products.
2016 | Ghaziabad, Uttar Pradesh (India) | Active
Replete Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -96.82%
- Profit Growth -1136.39%
- Ebitda 91.79%
- Net Worth -13.63%
- Total Assets -21.31%
About Replete Pharmaceuticals
Replete Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 March 2016 (Eight years and 11 months 7 days old ). Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Rajnish Singh and Nilu Singh serve as directors at the Company.
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74120UP2016PTC077553
- Company No.
077553
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 2016
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Pharma
Who are the key members and board of directors at Replete Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajnish Singh  | Director | 23-Mar-2016 | Current |
| Nilu Singh | Director | 23-Mar-2016 | Current |
Financial Performance of Replete Pharmaceuticals.
Replete Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 96.82% decrease. The company also saw a substantial fall in profitability, with a 1136.39% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Replete Pharmaceuticals?
In 2019, Replete Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Baba Mining And Resources Private Limited
Rajnish Singh and Nilu Singh are mutual person
- Sreesti Steel Private Limited
Rajnish Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Replete Pharmaceuticals?
Unlock and access historical data on people associated with Replete Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Replete Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Replete Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.